Enzalutamide and ruxolitinib.

Hosp Pharm

Dr. Hobson is a pharmacy practice resident (PGY1), Blount Memorial Hospital, Maryville, Tennessee.

Published: February 2013

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839480PMC
http://dx.doi.org/10.1310/hpj4802-104DOI Listing

Publication Analysis

Top Keywords

enzalutamide ruxolitinib
4
ruxolitinib complexity
4
complexity cancer
4
cancer chemotherapy
4
chemotherapy requires
4
requires pharmacists
4
pharmacists familiar
4
familiar complicated
4
complicated regimens
4
regimens highly
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!